» Articles » PMID: 24796769

Clinical Implications of Measuring Drug and Anti-drug Antibodies by Different Assays when Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial

Overview
Specialty Gastroenterology
Date 2014 May 7
PMID 24796769
Citations 47
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Cost-effective guidance of therapeutic strategy in Crohn's disease patients with secondary infliximab (IFX) treatment failure may be achieved by serum IFX and anti-IFX antibody (Ab) measurements by radioimmunoassay (RIA). This study investigated implications of using other techniques for this purpose.

Methods: This is a post hoc analysis of randomized clinical trial including 66 Crohn's disease patients with IFX failure in whom IFX and anti-IFX Ab measurements by RIA had been used for therapeutic guidance. Samples were additionally assessed by enzyme-linked immunosorbent assay (ELISA), homogeneous mobility shift assay (HMSA), and functional cell-based reporter gene assay (RGA).

Results: IFX detection was comparable between assays (82% RIA, 76% ELISA, 88% HMSA, and 74% RGA), and it correlated significantly (Pearson's r=0.91-0.97, P<0.0001). However, IFX concentrations varied systematically between all pair of assays except RIA-RGA. Anti-IFX Ab detection was variable (27% RIA, 9% ELISA, 33% HMSA, and 11% RGA), but correlated significantly (Pearson's r=0.77-0.96; P<0.0001). Anti-IFX Abs detected by RIA and HMSA were often from sera without drug-neutralizing activity (RGA). Assays agreed on classification of underlying mechanism for treatment failure in most cases (79-94%). The majority (74-88%) failed IFX owing to pharmacodynamic problems, or had noninflammatory pathophysiology for symptoms resembling relapse. Applied threshold for therapeutic vs. subtherapeutic IFX level influenced classifications. The four different assays did not differ in terms of the ability to predict response to interventions defined by the algorithm.

Conclusions: Despite variable analytical properties, common assays result in similar classifications and interventions in patients with IFX treatment failure, and with comparable clinical outcomes. Implications are, however, profound for the minority classified differently.

Citing Articles

Infliximab trough levels among patients with inflammatory bowel disease in correlation with infliximab treatment escalation: a cross-sectional study from a Greek tertiary center.

Orfanidou A, Katsanos K, Voulgaris T, Kofinas A, Christodoulou M, Konstandi M Ann Gastroenterol. 2024; 37(6):674-681.

PMID: 39568710 PMC: 11574158. DOI: 10.20524/aog.2024.0926.


Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations.

Nielsen O, Hammerhoj A, Ainsworth M, Gubatan J, DHaens G Drugs. 2024; 85(1):67-85.

PMID: 39532820 DOI: 10.1007/s40265-024-02115-3.


Immunogenicity and Loss of Effectiveness of Biologic Therapy for Inflammatory Bowel Disease Patients Due to Anti-Drug Antibody Development.

Velikova T, Sekulovski M, Peshevska-Sekulovska M Antibodies (Basel). 2024; 13(1).

PMID: 38534206 PMC: 10967499. DOI: 10.3390/antib13010016.


Management Decisions in Crohn's Disease Are Changed by Knowledge of Proactive and Reactive Testing of Antitumor Necrosis Factor Drug Levels.

Wu Y, Wen A, Selvanderan S, Xuan W, Andrews J, Koo J Crohns Colitis 360. 2023; 3(3):otab042.

PMID: 36776656 PMC: 9802446. DOI: 10.1093/crocol/otab042.


Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine.

Gehin J, Goll G, Brun M, Jani M, Bolstad N, Syversen S BioDrugs. 2022; 36(6):731-748.

PMID: 36315391 PMC: 9649489. DOI: 10.1007/s40259-022-00559-1.